165 results on '"Martinuzzo M"'
Search Results
2. PB1111 Lupus Anticoagulant Diagnosis: Real Life Rate of Interferences Due to Anticoagulant Treatment in a Laboratory of a High Complexity Hospital
3. PB1159 Critical Values in Hemostasis Laboratory. Analysis in a 3 Years Period Including Pandemics
4. PB1234 Prevalence of Studies with Acquired von Willebrand Syndrome Laboratory Profile at the Hospital Italiano de Buenos Aires (HIBA)
5. PO40 Hyperfiltration Syndrome as a Cause of Low Anti-Xa Activity Levels during Enoxaparin Treatment in a Critically Ill Patient
6. International collaborative study for the calibration of proposed International Standards for thromboplastin, rabbit, plain, and for thromboplastin, recombinant, human, plain
7. Evaluación de la hemostasia y heparinización de pacientes neonatos menores a 5 kg de peso sometidos a cirugía cardiovascular con pruebas viscoelásticas y pruebas de coagulación convencionales
8. Interaction Between Antiphospholipid Antibodies and Eicosanoids
9. Do PT and APTT sensitivities to factorsʼ deficiencies calculated by the H47-A2 2008 CLSI guideline reflect the deficiencies found in plasmas from patients?
10. Frequent False-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin
11. False positive results of Lupus Anticoagulant in plasmas of patients receiving LMWH or the new oral anticoagulants: PB 4.62–3
12. High specificity of Silica clotting time confirm/screen normalized ratio for LA diagnosis: PB 4.63–1
13. Laboratory estimation of expanded uncertainty of D dimer measurement by ELISA.: PB 4.51–5
14. Six SIGMA metric seems not to be applicable as a good quality tool for most laboratory tests of haemostasis: PB 3.53–5
15. New guidelines for lupus anticoagulant: sensitivity and specificity of cut-off values calculated with plasmas from healthy controls in mixing and confirmatory tests
16. Anti-β2glycoprotein I antibodies from leprosy patients do not show thrombogenic effects in an in vivo animal model
17. Antiphospholipid antibodies and antibodies to tissue factor pathway inhibitor in women with implantation failures or early and late pregnancy losses
18. A prospective study of antibodies to β2-glycoprotein I and prothrombin, and risk of thrombosis
19. Impact of different thrombloplastins on the international normalized ratio and model for end-stage liver disease in cirrhotics listed for liver transplantation: OP-19
20. Binding properties of antibodies to prothrombin and β2-glycoprotein I (β2-GPI) assayed by ELISA and dot blot
21. The haemostasis traffic light: a pragmatic tool for bleeding management
22. Increased Production of Platelet-Derived Thromboxane in Patients with Lupus Anticoagulant
23. Anti beta sub 2 glycoprotein I antibodies: detection and association with thrombosis
24. International collaborative study for the calibration of proposed International Standards for thromboplastin, rabbit, plain, and for thromboplastin, recombinant, human, plain
25. False-positive lupus anticoagulant results by DRVVT in the presence of rivaroxaban even at low plasma concentrations
26. Effects of Factor XIII Deficiency on Thromboelastography. Thromboelastography with Calcium and Streptokinase Addition is more Sensitive than Solubility Tests
27. Mulher ao cair da tarde: o sofrimento na poesia de Adélia Prado
28. Frequent False-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin
29. New guidelines for lupus anticoagulant: sensitivity and specificity of cut-off values calculated with plasmas from healthy controls in mixing and confirmatory tests
30. Prothrombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome
31. Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies
32. Autoantibodies to TFPI are associated with definite APS but not with infection-related aPL
33. Central retinal vein occlusion and thrombophilia risk factors
34. Heparin-platelet Factor 4 Induced Antibodies in Patients with either Autoimmune or Alloimmune Antiphospholipid Antibodies
35. Thrombophilic factors in chronic thromboembolic pulmonary hypertension
36. Low plasma protein Z levels in patients with antiphospholipid antibodies
37. High prevalence of antiphospholipid antibodies in leprosy: evaluation of antigen reactivity
38. Factor V Leiden and Prothrombin G 20210A Variant Are Risk Factors for Venous Thromboembolism in the Argentinean Population
39. Early occlusion of coronary by-pass associated with the presence of factor V Leiden and the prothrombin 20210A allele
40. Influence of Three Types of Automated Coagulometers on the International Sensitivity Index (ISI) of Rabbit, Human, and Recombinant Human Tissue Factor Preparations
41. Multicenter Evaluation of Lyophilized and Deep-frozen Plasmas for Assignment of the International Normalized Ratio
42. Pregnancy loss and autoantibodies against phospholipid-binding proteins
43. Activated protein C resistance in patients with anti-??2 glycoprotein I antibodies
44. Increased Plasma Thrombomodulin in Different Subgroups of Patients with Antiphospholipid and Anti β2 Glycoprotein I Antibodies
45. Reactivity to β2 Glycoprotein I Clearly Differentiates Anticardiolipin Antibodies from Antiphospholipid Syndrome and Syphilis
46. Anti β2 glycoprotein I antibodies: detection and association with thrombosis
47. Antiphospholipid Antibodies Enhance Thrombin-Induced Platelet Activation and Thromboxane Formation
48. Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant
49. Partial Neutralization of a Lupus Anticoagulant by Human Immunoglobulin
50. Anticuerpos antifosfolípidos y proteína Z.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.